Early Deferasirox Treatment in a Patient with Myelodysplastic Syndrome Results in a Long-Term Reduction in Transfusion Requirements

Publisher： Karger

E-ISSN： 1421-9662|121|1|19-20

ISSN： 0001-5792

Source： Acta Haematologica, Vol.121, Iss.1, 2009-03, pp. : 19-20

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Deferasirox Treatment Improved the Hemoglobin Level and Decreased Transfusion Requirements in Four Patients with the Myelodysplastic Syndrome and Primary Myelofibrosis

By  

Acta Haematologica, Vol. 120, Iss. 2, 2008-10 ,pp. : 70-74

Karger

Access to resources Recommend Favorite

Deferasirox Treatment Interruption in a Transfusion-Requiring Myelodysplastic Patient Led to Loss of Erythroid Response

By  

Acta Haematologica, Vol. 124, Iss. 1, 2010-07 ,pp. : 46-48

Karger

Access to resources Recommend Favorite

Long-Term Response in a Patient with del(5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge

By  

Case Reports in Oncology, Vol. 7, Iss. 1, 2014-04 ,pp. : 277-284

Karger

Access to resources Recommend Favorite

Cyclosporine A in the Treatment of a Patient with Immune Thrombocytopenia Accompanied by Myelodysplastic Syndrome and Nephrotic Syndrome

By  

Acta Haematologica, Vol. 110, Iss. 1, 2003-09 ,pp. : 36-40

Karger

Access to resources Recommend Favorite

Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia

By  

TRANSFUSION, Vol. 54, Iss. 6, 2014-06 ,pp. : 1542-1551

John Wiley & Sons Inc

Access to resources Recommend Favorite